Patients with cancer demonstrate particularly poor outcomes from COVID-19 . Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, has published results from a study that analyzed a cohort of 38,628 cancer patients to gain insight into why cancer patients have poor outcomes from COVID-19. Investigators identified that ACE2, TMPRSS2, and other proteases that are key factors necessary for viral attachment to and entry into target cells. Caris' study results have been published in Scientific Reports, A Nature Research Journal, finding substantial variability of expression of ACE2 and TMPRSS2 across tumor types while identifying subpopulations expressing ACE2 at very high levels. This study provides the first systematic assessment of RNA expression of key molecules involved in the infectious process, and offers a biological explanation for why cancer patients do poorly when afflicted with COVID-19.